A Proof of Concept and Dose Ranging Study in Patients With Rheumatoid Arthritis

PHASE2CompletedINTERVENTIONAL
Enrollment

373

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

April 30, 2009

Study Completion Date

April 30, 2009

Conditions
Rheumatoid Arthritis
Interventions
DRUG

AZD5672

20 mg oral, once daily

DRUG

Etanercept

50 mg, subcutaneous injection, weekly

DRUG

Placebo

placebo, oral, once daily

DRUG

AZD5672

50 mg oral, once daily

DRUG

AZD5672

100 mg oral, once daily

DRUG

AZD5672

150 mg oral, once daily

Trial Locations (49)

Unknown

Research Site, Blagoevgrad

Research Site, Plovdiv

Research Site, Sofia

Research Site, Medellín

Research Site, Bogotá

Research Site, Bucaramanga

Research Site, Česká Lípa

Research Site, České Budějovice

Research Site, Hlučín

Research Site, Pardubice

Research Site, Prague

Research Site, Praha 11 - Chodov

Research Site, Zlín

Research Site, Békéscsaba

Research Site, Budapest

Research Site, Debrecen

Research Site, Kecskemét

Research Site, Makó

Research Site, Sopron

Research Site, Siena

Research Site, Valmiera

Research Site, Birkirkara

Research Site, Bialystok

Research Site, Działdowo

Research Site, Krakow

Research Site, Lublin

Research Site, Sopot

Research Site, Szczecin

Research Site, Torun

Research Site, Warsaw

Research Site, Wroclaw

Research Site, Brasov

Research Site, Bucharest

Research Site, Ploieşti

Research Site, Saint Petersburg

Research Site, Yaroslavl

Research Site, Belgrade

Research Site, Niška Banja

Research Site, Banská Bystrica

Research Site, Bratislava

Research Site, Piešťany

Research Site, Pretoria

Research Site, Durban

Research Site, Cape Town

Research Site, Donetsk

Research Site, Ivano-Frankivsk

Research Site, Kiev

Research Site, Kyiv

Research Site, Simferopol

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY